Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HeXun Biosciences CoROCO:6986 22 PE Ratio (TTM) is 16.01 as of Aug. 04, 2026, which is 35% below its 10-year median of 24.81. GuruFocus rates ROCO:6986 with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 270 Biotechnology companies, HeXun Biosciences Co ranks worse than 67.78% on this metric.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-08-04), HeXun Biosciences Co's share price is
NT$43.70.
HeXun Biosciences Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was NT$2.73. Therefore, HeXun Biosciences Co's PE Ratio (TTM) for today is 16.01.
Good Sign:
HeXun Biosciences Co Ltd stock PE Ratio (=16.01) is close to 2-year low of 16.01.
The historical rank and industry rank for HeXun Biosciences Co's PE Ratio (TTM) or its related term are showing as below:
ROCO:6986'
s PE Ratio (TTM) Range Over the Past 10 Years
Min: 16.01 Med: 24.81 Max: 111.97
Current: 16.01
During the past 6 years, the highest PE Ratio (TTM) of HeXun Biosciences Co was 111.97. The lowest was 16.01. And the median was 24.81.
ROCO:6986's PE Ratio (TTM) is ranked worse than 67.78% of 270
companies
in the Biotechnology industry
Industry Median: 26.525
vs ROCO:6986: 16.01
HeXun Biosciences Co's EPS (Basic) for the
three
months ended in Mar. 2026 was NT$0.60.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was NT$2.73.
HeXun Biosciences Co (ROCO:6986) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
HeXun Biosciences Co PE Ratio (TTM) Related Terms
HeXun Biosciences Co PE Ratio (TTM) Historical Data
* Premium members only.
The historical data trend for HeXun Biosciences Co's PE Ratio (TTM) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6986 vs VRTX, REGN, RVMD: PE Ratio (TTM) Comparison
For the Biotechnology subindustry, HeXun Biosciences Co's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeXun Biosciences Co PE Ratio (TTM) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HeXun Biosciences Co's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where HeXun Biosciences Co's PE Ratio (TTM) falls into.
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
HeXun Biosciences Co's Share Price of today is NT$43.70.
HeXun Biosciences Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.73.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
HeXun Biosciences Co (ROCO:6986) has a PE Ratio (TTM) of 16.01 as of Aug. 04, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on HeXun Biosciences Co and its competitors. This is 35% below median its historical median of 24.81. Over the past decade, HeXun Biosciences Co's PE Ratio (TTM) has ranged from 16.01 to 111.97. According to the industry distribution chart, HeXun Biosciences Co ranks #183 out of 270 companies in the Biotechnology industry, placing it in the top 67.8%.
Is HeXun Biosciences Co's PE Ratio (TTM) too high?
HeXun Biosciences Co's current PE Ratio (TTM) of 16.01 is 35% below median its 10-year median of 24.81. Over the past 10 years, this metric has ranged from a low of 16.01 to a high of 111.97. The Biotechnology industry median PE Ratio (TTM) is 26.53. HeXun Biosciences Co's value of 16.01 is 39.6% below this industry median. Based on the distribution chart, HeXun Biosciences Co ranks #183 out of 270 companies in the Biotechnology industry, which is below the industry midpoint. Overall, HeXun Biosciences Co has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's PE Ratio (TTM) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HeXun Biosciences Co ranks #183 out of 270 companies for PE Ratio (TTM). This places HeXun Biosciences Co in the lower half of its industry. The industry median PE Ratio (TTM) is 26.53. HeXun Biosciences Co's value of 16.01 is 39.6% below this benchmark. Historically, HeXun Biosciences Co's own PE Ratio (TTM) has ranged from 16.01 to 111.97 over the past decade. While the company's 10-year median is 24.81 vs. the industry median of 26.53, HeXun Biosciences Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Biotechnology company?
The median PE Ratio (TTM) among Biotechnology companies is 26.53, based on 270 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HeXun Biosciences Co's current PE Ratio (TTM) of 16.01 is 39.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on HeXun Biosciences Co and its competitors. For the Biotechnology industry, the median PE Ratio (TTM) is 26.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HeXun Biosciences Co's current PE Ratio (TTM) is 16.01, which is 35% below median its own 10-year median of 24.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
HeXun Biosciences Co (ROCO:6986) has a current PE Ratio (TTM) of 16.01. The current PE Ratio (TTM) is 16.01, which is 35% below median its 10-year median of 24.81 and 39.6% below the Biotechnology industry median of 26.53. HeXun Biosciences Co's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current PE Ratio (TTM) is 16.01 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
22GF Score
Get the complete analysis for ROCO:6986
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6986 has been successfully added to your 
